Chronic Dosing Protocol: AOD9604 administered intraperitoneally at 250 g/kg/day hGH administered at 1 mg/kg/day Treatment duration: 1428 days depending on cohort Daily administration via intraperitoneal injection Acute Testing Protocol: Single AOD9604 dose: 2 mg/kg 3-AR agonist BRL37344: 250 g/kg (for comparison) Indirect calorimetry measurements performed Measured Outcomes: Body weight, food intake, white adipose tissue (WAT) and brown adipose tissue (BAT) weights, plasma glycerol levels (indicating lipolysis), and 3-AR mRNA expression in adipose tissue
Ewing, B., Hillier, L., Wendl, M
High oral bioavailability and membrane permeability ensure effective systemic distribution without complex preparation requirements
The main consideration is ensuring adequate hydration and electrolytes, as fasting plus peptide use may increase demands on both
We are proud of our approach, and our host of satisfied and return customers certainly speaks for itself
A few honest comparison notes: Against fillers and Botox: GHK-Cu supports skin quality